Coherus BioSciences, Inc. (CHRS) Tuesday said it has agreed to buy back about $170 million of its 1.500% convertible senior subordinated notes due 2026 at its principal plus interest amount.
The buyback is conditioned upon the closing of the previously announced sale of the UDENYCA franchise following an agreement with Intas Pharmaceuticals Ltd.
The company also intends to repurchase the remaining notes after the closing of the buyback of about $60 million.
Additionally, Coherus said that the note holders party to the repurchases have agreed to provide their consent to adopt certain proposed amendments to the indenture.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.